


# COVID-19 Outpatient Therapies

Monoclonal antibodies, remdesivir, molnupiravir, Paxlovid



## Outreach & Referral Criteria and Access Process

Patients are screened for eligibility for outpatient Covid therapy via two distinct processes. Please see below for details, but don't hesitate to refer patients you feel may benefit from therapy.

NOTE: Demand for these therapies is currently exceeding supplies. [NIH Statement on Patient Prioritization](#) is being utilized to provide therapy to patients at highest risk for progression to severe illness or hospitalization.

### Automated Outreach

#### Process

COVID-19 test positive at Nebraska Medicine



Epic screens for high risk criteria (below)



Patients evaluated and called by Pharmacy Outreach team to discuss therapy



Infusion arranged if desired

#### Automated High-Risk screening criteria

- Age  $\geq$  65 years of age
- BMI  $\geq$  35 or BMI  $>$ 85<sup>th</sup> percentile for age/gender if age 12-17
- Diabetes
- Chronic Kidney Disease
- Immunosuppression
- Cardiovascular Disease
- Hypertension
- COPD/asthma, reactive airway or other chronic respiratory disease requiring drug therapy
- Sickle cell disease
- Congenital acquired heart disease
- Neurodevelopmental disorders
- Pregnancy

### Provider Initiated Referral

Contact the [Pharmacy Outreach Team](#) to request manual evaluation for:

- Patients not meeting automated criteria (can still be treated if meeting expanded EUA inclusion criteria; these are found on the [CDC website](#), but are not all\_inclusive)
- Patients with a positive test outside Nebraska Medicine laboratory
- Consideration for post exposure prophylaxis

#### Referral Process

1. Document note in One Chart reflecting your conversation with the patient including: symptoms, symptom onset date, and reason(s) they are to be considered for therapy
2. Scan outside test results into One Chart (if not possible attach to email)
3. Send an email to [pharmacyoutreachteam@nebraskamed.com](mailto:pharmacyoutreachteam@nebraskamed.com) with the MRN of the patient
4. Pharmacy will review the documentation and call the patient to discuss therapy within 24 hours

**NOTE:** If your patient is symptomatic and appears to meet high-risk criteria but does not yet have a positive test or has completed only a home test, please order SARS-CoV-2 testing through the Nebraska Medicine laboratory.

For more information see: [COVID-19 Monoclonal Antibody \(mAb\) Therapy Process](#)